Photo detail

Athena Countouriotis
Chief Executive Officer
Turning Point Therapeutics, Inc

Stories this photo appears in:

Bristol Myers Squibb Buys Turning Point

BIOTECH: $4.1B Deal Expands ‘Oncology Franchise’

Bristol Myers Squibb (BMS) is further strengthening its ties to San Diego. On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego.